Literature DB >> 7999767

Mechanism-based inhibition of thymidylate synthase by 5-(trifluoromethyl)-2'-deoxyuridine 5'-monophosphate.

J W Eckstein1, P G Foster, J Finer-Moore, Y Wataya, D V Santi.   

Abstract

Thymidylate synthase (TS) from Lactobacillus casei is inhibited by 5-(trifluoromethyl)-2'-deoxyuridine 5'-monophosphate (CF3dUMP). CF3dUMP binds to the active site of TS in the absence of 5,10-methylenetetrahydrofolate, and attack of the catalytic nucleophile cysteine 198 at C6 of the pyrimidine leads to activation of the trifluoromethyl group and release of fluoride ion. Subsequently, the activated heterocycle reacts with a nucleophile of the enzyme to form a moderately stable covalent complex. Proteolytic digestion of TS treated with [2'-3H]CF3dUMP, followed by sequencing of the labeled peptides, revealed that tyrosine 146 and cysteine 198 are covalently bound to the inhibitor in the enzyme-inhibitor complex. The presence of dithiothreitol (DTT) or beta-mercaptoethanol resulted in the breakdown of the covalent complex, and products from the breakdown of the complex were isolated and characterized. The three-dimensional structure of the enzyme-inhibitor complex was determined by X-ray crystallography, clearly demonstrating covalent attachment of the nucleotide to tyrosine 146. A chemical reaction mechanism for the inhibition of TS by CF3dUMP is presented that is consistent with the kinetic, biochemical, and structural results.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7999767     DOI: 10.1021/bi00254a018

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  20 in total

Review 1.  TAS-102, a novel antitumor agent: a review of the mechanism of action.

Authors:  Heinz-Josef Lenz; Sebastian Stintzing; Fotios Loupakis
Journal:  Cancer Treat Rev       Date:  2015-06-06       Impact factor: 12.111

2.  Trifluorothymidine exhibits potent antitumor activity via the induction of DNA double-strand breaks.

Authors:  Norihiko Suzuki; Fumio Nakagawa; Mamoru Nukatsuka; Masakazu Fukushima
Journal:  Exp Ther Med       Date:  2011-03-21       Impact factor: 2.447

3.  Prodrug activation by Cryptosporidium thymidine kinase.

Authors:  Xin E Sun; Lisa Sharling; Mani Muthalagi; Devaraja G Mudeppa; Krzysztof W Pankiewicz; Krzysztof Felczak; Pradipsinh K Rathod; Jan Mead; Boris Striepen; Lizbeth Hedstrom
Journal:  J Biol Chem       Date:  2010-03-15       Impact factor: 5.157

4.  5,10-Methylene-5,6,7,8-tetrahydrofolate conformational transitions upon binding to thymidylate synthase: molecular mechanics and continuum solvent studies.

Authors:  Adam Jarmuła; Piotr Cieplak; William R Montfort
Journal:  J Comput Aided Mol Des       Date:  2005-02       Impact factor: 3.686

Review 5.  TAS-102: a novel antimetabolite for the 21st century.

Authors:  Nataliya Uboha; Howard S Hochster
Journal:  Future Oncol       Date:  2015-11-30       Impact factor: 3.404

6.  Trifluridine selectively inhibits cell growth and induces cell apoptosis of triple-negative breast cancer.

Authors:  Juan Li; Jie Liu; Riqi Wang; He Chen; Cui Li; Minggang Zhao; Fang He; Yaochun Wang; Peijun Liu
Journal:  Am J Cancer Res       Date:  2020-02-01       Impact factor: 6.166

7.  Relative free energies of binding to thymidylate synthase of 2- and/or 4-thio and/or 5-fluoro analogues of dUMP.

Authors:  Adam Jarmuła; Piotr Cieplak; Andrzej Leś; Wojciech Rode
Journal:  J Comput Aided Mol Des       Date:  2003-10       Impact factor: 3.686

Review 8.  Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies.

Authors:  Godefridus J Peters
Journal:  Ther Adv Med Oncol       Date:  2015-11       Impact factor: 8.168

9.  The Hollow Fibre Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells.

Authors:  O H Temmink; H-J Prins; E van Gelderop; G J Peters
Journal:  Br J Cancer       Date:  2006-12-19       Impact factor: 7.640

10.  Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells.

Authors:  O H Temmink; E K Hoebe; K van der Born; S P Ackland; M Fukushima; G J Peters
Journal:  Br J Cancer       Date:  2007-01-29       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.